 | | Vol. 23.26 – 25 July, 2022 |
| |
|
|
| Researchers engineered programmed death ligand-1 and cytotoxic T lymphocyte antigen 4 immunoglobulin fusion protein–modified mesenchymal stromal cells as accessory cells for islet cotransplantation.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators analyzed the role of different helper lipids and component ratios in plasmid DNA lipid nanoparticle-mediated gene delivery in vitro and in vivo.
[Nature Communications] |
|
|
|
| Scientists genetically engineered human pluripotent stem cells with synthetic CARs and differentiated them into functional neutrophils by implementing a chemically defined platform.
[Cell Reports] |
|
|
|
| To explore the therapeutic utility of switchable CAR-Ts targeting the receptor tyrosine kinase ROR1, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers.
[Oncogene] |
|
|
|
| In Atoh1-GFP;Kcnq4+/G229D mice, recapitulating a novel mutation, the authors identified that in a hereditary hearing loss pedigree, the high-efficiency editing of CRISPR/Cas9 in hair cells was precisely detected by sorting out labeled cells, compared with only 1.45% efficiency in the whole cochlear tissue.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| LpMab-2 (Lp2)-CAR transduced T cells (Lp2-CAR-T) specifically targeted podoplanin (PDPN)-expressing glioma cells, while sparing the PDPN-expressing normal cells. Lp2-CAR-T also killed patient-derived glioma stem cells, demonstrating its clinical potential against glioblastoma.
[Molecular Therapy-Oncolytics] |
|
|
|
| Researchers investigated the therapeutic effects of dry-preserved multi-layered fibroblast cell sheets on cutaneous ulcers. In wounds created on diabetic mice, the dry sheet-treatment groups using autologous or allogeneic cells showed accelerated wound closure compared with that in the no-treatment group.
[Scientific Reports] |
|
|
|
| The authors generated CAR-T cells armored with IL-7 to prolong the persistence of infused T cells, particularly CD4+ T cells, and enhanced anti-tumor response.
[Scientific Reports] |
|
|
|
| In in vivo study, an ectopic nude mouse model and an in situ beagle dog model were established to investigate the possibility of pulp regeneration by implanting collagen gel loading bone morphogenetic protein 7.
[International Journal of Oral Science] |
|
|
|
|
| Scientists describe the various approaches to augment natural killer (NK) cell cytotoxicity and longevity, evaluate challenges and opportunities, and reflect on how lessons learned from the clinic will guide the design of next-generation NK cell products that will address the unique complexities of each cancer.
[Nature Reviews Cancer] |
|
|
|
| The authors provide an overview of gene therapies for central nervous system diseases and describe recent advances in the development of nanomedicines, including the specific applications that those nanomedicines are harnessed to deliver gene therapies.
[Advanced Science] |
|
|
|
| Investigators describe three cases of non-relapse cytopenias following allogeneic stem cell transplantation: graft failure with graft rejection representing cytopenias with minimal donor chimerism, poor graft function representing cytopenias with complete donor chimerism, and cytopenias with mixed donor chimerism.
[Bone Marrow Transplantation] |
|
|
|
|
| Vertex Pharmaceuticals, Inc. and Verve Therapeutics, Inc. announced an exclusive, four-year global research collaboration focused on discovering and developing an in vivo gene editing program for a single undisclosed liver disease.
[Vertex Pharmaceuticals Incorporated] |
|
|
|
| Sosei Group Corporation and Cancer Research UK announced the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.
[Sosei Group Corporation] |
|
|
|
| Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that it is leading a consortium that has been awarded a €4 million grant from Horizon Europe, the European Union’s key funding program for research and innovation.
[Achilles Therapeutics plc] |
|
|
|
|
| October 10 – 12, 2022
Lausanne, Switzerland |
|
|
|
|
|
| | US Department of Health and Human Services – Research Triangle Park, North Carolina, United States |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Michigan Medicine – Ann Arbor, Michigan, United States |
|
|
|
| | Warsaw University of Technology – Warsaw, Poland |
|
|
|
| | University Hospital of North Norway – Tromsø, Norway |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
